The Research Progress On Castrate-Resistant Prostate Cancer

Prostate cancer is one of the life threatening disorders for human being,which has a high incidence over the world.Androgen and the androgen receptor(AR)are critical effectors of prostate cancer.Consequently,androgen deprivation therapy(ADT)is typically employed as a first-line treatment for prostate cancer patients.While initial responses are generally positive,most prostate tumors frequently recur and progress to castrate-resistant prostate cancer(CRPC).CRPC has an extremely poor prognosis.The mechanism of occurrence and progress of CRPC is very complex,and it has yet not been fully elucidated.The effect of past clinical treatment to improve the patients' survival and quality of life is limited.Recently,several new therapeutic agents have been developed,some of which are approved by FDA or on clinical trials,including androgen synthesis(abiraterone),AR inhibitor(enzalutamide),immunotherapy(sipuleucel-T),radiopharmaceutical(Radium-223),and chemotherapeutic agent(cabazitaxel).Therefore,there are more choices for the treatment of CRPC patients and the strategies of the comprehensive therapy have undergone great changes.In this article we review the research progress of castrate resistant prostate cancer.